Clearmind Medicine Inc.

As of July 31, 2026, Clearmind Medicine Inc. carries a market capitalization of 20.08M, placing it among publicly traded companies globally. Its enterprise value stands at 5.95M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of July 31, 2026, Clearmind Medicine Inc. has 1.49M shares outstanding.

These figures are as of July 31, 2026.

As of July 31, 2026, Clearmind Medicine Inc. maintains a current ratio of 4.31, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.89, indicating elevated leverage, while an interest coverage ratio of -1,189.66 demonstrates limited ability to service its debt obligations.

Over the twelve months ended July 31, 2026, Clearmind Medicine Inc. posted a negative return on equity (ROE) of -106.98, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -71.81, reflecting losses generated across the asset base.

Over the twelve months ended July 31, 2026, Clearmind Medicine Inc. recorded 12,695.00 in income tax expense. The company reported a pretax loss of -7.48M and -7.50M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Clearmind Medicine Inc.'s stock has declined approximately 99.81% over the past 52 weeks. The 50-day moving average sits at 9.15, while the 200-day moving average is 53.48.

Over the twelve months ended July 31, 2026, Clearmind Medicine Inc. generated - - in revenue and converted that into -7.50M in net income, yielding earnings per share of -14.88. EBITDA reached -8.81M, while operating income came in at -8.87M.

As of July 31, 2026, Clearmind Medicine Inc. holds 15.93M in cash and equivalents against 1.80M in total debt, resulting in a net debt position of -10.41M. Total book value stands at 12.95M, with working capital of 12.77M providing operational flexibility.

Clearmind Medicine Inc. produced -7.07M in operating cash flow over the twelve months ended July 31, 2026.

These figures cover the twelve months ended July 31, 2026. Free cash flow yield is negative at -103.81: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -87.48, meaning Clearmind Medicine Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Clearmind Medicine Inc.'s most recent stock split took place on October 5, 2026 with a 8:1 split ratio.

As of July 31, 2026, Clearmind Medicine Inc. has an Altman Z-Score of -0.67, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.